New hope to stop High-Risk breast Cancer's return
NCT ID NCT07242352
Summary
This trial is for people with a specific type of early breast cancer (ER+/HER2-) that is at a high risk of coming back. It will test if starting treatment with a new drug called elacestrant, with or without another standard drug, for 5 years is better at keeping the cancer away than the current standard hormone therapy alone. The goal is to see if this approach helps patients live longer without their cancer returning.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.